Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

Monitoring Pc 4 photodynamic therapy in clinical trials of cutaneous T-cell lymphoma using noninvasive spectroscopy.

Lee TK, Baron ED, Foster TH.

J Biomed Opt. 2008 May-Jun;13(3):030507. doi: 10.1117/1.2939068.

2.

Silicon phthalocyanine (Pc 4) photodynamic therapy is a safe modality for cutaneous neoplasms: results of a phase 1 clinical trial.

Baron ED, Malbasa CL, Santo-Domingo D, Fu P, Miller JD, Hanneman KK, Hsia AH, Oleinick NL, Colussi VC, Cooper KD.

Lasers Surg Med. 2010 Dec;42(10):728-35. doi: 10.1002/lsm.20984.

3.

Optimization of a nanomedicine-based silicon phthalocyanine 4 photodynamic therapy (Pc 4-PDT) strategy for targeted treatment of EGFR-overexpressing cancers.

Master AM, Livingston M, Oleinick NL, Sen Gupta A.

Mol Pharm. 2012 Aug 6;9(8):2331-8. doi: 10.1021/mp300256e. Epub 2012 Jul 19.

4.

Activated T cells exhibit increased uptake of silicon phthalocyanine Pc 4 and increased susceptibility to Pc 4-photodynamic therapy-mediated cell death.

Soler DC, Ohtola J, Sugiyama H, Rodriguez ME, Han L, Oleinick NL, Lam M, Baron ED, Cooper KD, McCormick TS.

Photochem Photobiol Sci. 2016 Jun 8;15(6):822-31. doi: 10.1039/c6pp00058d. Epub 2016 May 10.

5.

Immunosuppressive effects of silicon phthalocyanine photodynamic therapy.

Reddan JC, Anderson CY, Xu H, Hrabovsky S, Freye K, Fairchild R, Tubesing KA, Elmets CA.

Photochem Photobiol. 1999 Jul;70(1):72-7.

PMID:
10420845
6.

Photodynamic therapy with the phthalocyanine photosensitizer Pc 4 of SW480 human colon cancer xenografts in athymic mice.

Whitacre CM, Feyes DK, Satoh T, Grossmann J, Mulvihill JW, Mukhtar H, Oleinick NL.

Clin Cancer Res. 2000 May;6(5):2021-7.

7.

Phthalocyanine photodynamic therapy: disparate effects of pharmacologic inhibitors on cutaneous photosensitivity and on tumor regression.

Anderson C, Hrabovsky S, McKinley Y, Tubesing K, Tang HP, Dunbar R, Mukhtar H, Elmets CA.

Photochem Photobiol. 1997 May;65(5):895-901.

PMID:
9155263
8.
9.

Photodynamic therapy with the phthalocyanine photosensitizer Pc 4: the case experience with preclinical mechanistic and early clinical-translational studies.

Miller JD, Baron ED, Scull H, Hsia A, Berlin JC, McCormick T, Colussi V, Kenney ME, Cooper KD, Oleinick NL.

Toxicol Appl Pharmacol. 2007 Nov 1;224(3):290-9. Epub 2007 Feb 15. Review.

10.

Successful cutaneous delivery of the photosensitizer silicon phthalocyanine 4 for photodynamic therapy.

Lam M, Hsia AH, Liu Y, Guo M, Swick AR, Berlin JC, McCormick TS, Kenney ME, Oleinick NL, Cooper KD, Baron ED.

Clin Exp Dermatol. 2011 Aug;36(6):645-51. doi: 10.1111/j.1365-2230.2010.03989.x. Epub 2011 May 30. Review.

11.

Apoptosis is an early event during phthalocyanine photodynamic therapy-induced ablation of chemically induced squamous papillomas in mouse skin.

Agarwal R, Korman NJ, Mohan RR, Feyes DK, Jawed S, Zaim MT, Mukhtar H.

Photochem Photobiol. 1996 Apr;63(4):547-52.

PMID:
8934768
12.

A comparative analysis of silicon phthalocyanine photosensitizers for in vivo photodynamic therapy of RIF-1 tumors in C3H mice.

Anderson CY, Freye K, Tubesing KA, Li YS, Kenney ME, Mukhtar H, Elmets CA.

Photochem Photobiol. 1998 Mar;67(3):332-6.

PMID:
9523532
13.

Topical 5-ALA photodynamic therapy for the treatment of cutaneous T-cell lymphoma.

Leman JA, Dick DC, Morton CA.

Clin Exp Dermatol. 2002 Sep;27(6):516-8. Review.

PMID:
12372098
14.

Fluence rate-dependent photobleaching of intratumorally administered Pc 4 does not predict tumor growth delay.

Baran TM, Foster TH.

Photochem Photobiol. 2012 Sep-Oct;88(5):1273-9. doi: 10.1111/j.1751-1097.2012.01171.x. Epub 2012 Jun 6.

15.

Topical photodynamic therapy for patients with therapy-resistant lesions of cutaneous T-cell lymphoma.

Coors EA, von den Driesch P.

J Am Acad Dermatol. 2004 Mar;50(3):363-7. Erratum in: J Am Acad Dermatol. 2004 Jun;50(6):849.

PMID:
14988676
16.

Targeted iron-oxide nanoparticle for photodynamic therapy and imaging of head and neck cancer.

Wang D, Fei B, Halig LV, Qin X, Hu Z, Xu H, Wang YA, Chen Z, Kim S, Shin DM, Chen ZG.

ACS Nano. 2014 Jul 22;8(7):6620-32.

17.

Photodynamic therapy of cutaneous lymphoma using 5-aminolevulinic acid topical application.

Orenstein A, Haik J, Tamir J, Winkler E, Trau H, Malik Z, Kostenich G.

Dermatol Surg. 2000 Aug;26(8):765-9; discussion 769-70.

PMID:
10940064
18.

Photodynamic therapy with Pc 4 induces apoptosis of Candida albicans.

Lam M, Jou PC, Lattif AA, Lee Y, Malbasa CL, Mukherjee PK, Oleinick NL, Ghannoum MA, Cooper KD, Baron ED.

Photochem Photobiol. 2011 Jul-Aug;87(4):904-9. doi: 10.1111/j.1751-1097.2011.00938.x. Epub 2011 Jun 13.

19.

Spotlighting the role of photodynamic therapy in cutaneous malignancy: an update and expansion.

Ross K, Cherpelis B, Lien M, Fenske N.

Dermatol Surg. 2013 Dec;39(12):1733-44. doi: 10.1111/dsu.12319. Epub 2013 Oct 9. Review.

PMID:
24118243
20.

Photodynamic therapy for the treatment of skin disease.

Kendall CA, Morton CA.

Technol Cancer Res Treat. 2003 Aug;2(4):283-8. Review.

PMID:
12892510

Supplemental Content

Support Center